Table of contents

Abstracts

• 01 SLE burden of disease: the patient’s perspective (30 August, 2023)

  Jeanette Andersen
• 02 Challenges in the development of a universal SLE patient charter (30 August, 2023)

  Eloisa Bonfá
• 03 Disease modification and prevention of damage (30 August, 2023)

  Murray Urowitz
• 04 Biologic disease modifying drugs in SLE (30 August, 2023)

  Maria Dall’Era
• 05 Approved biologics for SLE: which to try first and in which patients? – The case for belimumab (30 August, 2023)

  Ronald van Vollenhoven
• 06 Approved biologics for SLE: which to try first and in which patients? – The case for anifrolumab (30 August, 2023)

  Eric Morand
• 07 New (ACR/EULAR) antiphospholipid syndrome classification criteria (30 August, 2023)

  Doruk Erkan
• 08 Disruption points in lupus patient pathways (30 August, 2023)

  Laurent Arnaud
• 09 Herpes zoster prevalence and recommendations from clinical trial safety data (30 August, 2023)

  Richard Furie
• 10 Updated immunization guidelines (30 August, 2023)

  Nancy Agmon-Levin
• 11 What is happening in the world of publishing? (30 August, 2023)

  Ronald van Vollenhoven
• 12 Management of paediatric lupus (30 August, 2023)

  Elizabeth Ang
• 13 Management of paediatric lupus (30 August, 2023)

  Joan Calzada-Hernández
• 14 Management of cardiovascular involvement in SLE (30 August, 2023)

  Bernardo A Pons-Estel
• 15 Management of cardiovascular involvement in SLE (30 August, 2023)

  Gerard Espinosa
• 16 Management of lupus nephritis (30 August, 2023)

  YK Onno Teng
• 17 Management of lupus nephritis (30 August, 2023)

  Luis Quintana
• 18 Management of musculoskeletal involvement in SLE (30 August, 2023)

  Andrea Doria
• 19 Management of musculoskeletal involvement in SLE (30 August, 2023)

  José A Gómez-Puerta
• 20 Management of skin involvement in SLE (30 August, 2023)

  Annegret Kuhn
• 21 Management of skin involvement in SLE (30 August, 2023)

  Antonio Guilabert Vidal
• 22 The patient´s voice (30 August, 2023)

  Jeanette Andersen
• 23 The nurse’s perspective (30 August, 2023)

  Ada Ferenkeh-Koroma
• 24 ERN-ReCONNET: a model for patient-healthcare provider collaboration (30 August, 2023)

  Marta Mosca
• 25 Disease modification in SLE: an introduction (30 August, 2023)

  Ronald van Vollenhoven
• 26 Optimizing steroid-sparing drugs in SLE (30 August, 2023)

  Guillermo Ruiz-Irastorza
• 27 Disease modification in lupus nephritis (30 August, 2023)

  Manuel Praga
• 28 JAK-STAT inhibitors in systemic lupus erythematosus (30 August, 2023)

  Antonis Fanouriakis
• 29 Plasmacytoid dendritic cells as a treatment target (30 August, 2023)

  Richard Furie
• 30 CAR-T: from our cancer experience to other options (30 August, 2023)

  Manel Juan
• 31 Other targets: expectations from research on pathogenic mechanisms (30 August, 2023)

  Thomas Dörner
• 32 Optimising lupus drug trial designs (30 August, 2023)

  Eric Morand
• 33 Autoimmune encephalitis (30 August, 2023)

  Eugenia Martinez-Hernandez
• 34 Interstitial lung disease (30 August, 2023)

  Vanessa Smith
• 35 Systemic capillary leak syndrome (30 August, 2023)

  Zahir Amoura